Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Previous Page Next Page

The information in this section is not country-specific and may contain information that is outside the approved indications in the country in which you are located.

This site contains information and education for healthcare professionals.


  1. Explore the importance of TRK fusion proteins as a therapeutic target and understand the clinical use of TRK inhibitors.
  2. Explain the mechanisms behind TRK fusion-driven tumour biology.
  3. Provide an overview of the different techniques used for NTRK gene fusion testing.
  4. Provide recommendations on testing for TRK fusion proteins.

Learning outcomes

The learning outcomes following completion of these modules include:

  • Knowing how and why TRK fusion proteins are a therapeutic target for patients across multiple tumour types.
  • Understand the advantages of genomic profiling for NTRK gene fusions and which patients to test.
  • Ability to interpret genomic profiling results and select the patients most likely to benefit from TRK inhibitor therapy.
  • Knowledge of the clinical data for TRK inhibitors that informs treatment decision making.
  • Knowledge and understanding of the different methodologies used for NTRK gene fusion testing.

Expert contributors

Information included in this website is compiled from review of the medical literature and expert guidance from:

  • Prof Ezra Cohen (medical oncologist at the Moores Cancer Center, San Diego, USA)
  • Prof. Fernando Lopez-Rios (molecular and surgical pathologist at Hospital Universitario 12 de Octubre, Madrid, Spain)
  • Dr. Jaclyn Hechtman (molecular and surgical pathologist at Memorial Sloan Kettering Cancer Center, New York, USA)
  • Prof. Frederique Penault-Llorca (molecular and surgical pathologist at the Comprehensive Regional Cancer Institute Centre Jean PERRIN, Clermont-Ferrand, France)
  • Assoc. Prof. Gerald Prager (medical oncologist at the Medical University of Vienna, Austria)
  • Prof. Christian Rolfo (medical oncologist at The Tisch Cancer Institute at Mount Sinai Health System, New York, USA)
  • Prof. Andrea Sartore-Bianchi (medical oncologist at Ospedale Niguarda and University of Milano, Italy)
  • Dr. Silvia Stacchiotti (medical oncologists at Oncologia Medica 2 at Fondazione IRCCS Istituto Nazionale Tumori, Milano, Italy)

Other general information

The section was created in 2019 and updated in 2022 (cut-off date for publications included is June 2022) to provide information on key related topics, including:

  • How and why TRK fusion proteins are a potential therapeutic target for selected patients across multiple tumour types.
  • Which patients may benefit from TRK inhibitor therapy and, therefore, which patients to test?
  • The different tests available and under development that can be used to identify NTRK gene fusions and to select patients who are candidates for TRK inhibitor treatment.
  • Which patients to treat with TRK inhibitors based on genomic profiling results.
  • How to select the right treatment for the right patient using treatment options based on genomic profiling results and available clinical data

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.